Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging

Hong Jun Cho, Sung Jin Lee, Sung Jun Park, Chang H. Paik, Sang Myung Lee, Sehoon Kim, Yoon Sik Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A disulfide-bridged cyclic RGD peptide, named iRGD (internalizing RGD, c(CRGDK/RGPD/EC)), is known to facilitate tumor targeting as well as tissue penetration. After the RGD motif-induced targeting on αv integrins expressed near tumor tissue, iRGD encounters proteolytic cleavage to expose the CendR motif that promotes penetration into cancer cells via the interaction with neuropilin-1. Based on these proteolytic cleavage and internalization mechanism, we designed an iRGD-based monolithic imaging probe that integrates multiple functions (cancer-specific targeting, internalization and fluorescence activation) within a small peptide framework. To provide the capability of activatable fluorescence signaling, we conjugated a fluorescent dye to the N-terminal of iRGD, which was linked to the internalizing sequence (CendR motif), and a quencher to the opposite C-terminal. It turned out that fluorescence activation of the dye/quencher-conjugated monolithic peptide probe requires dual (reductive and proteolytic) cleavages on both disulfide and amide bond of iRGD peptide. Furthermore, the cleavage of the iRGD peptide leading to fluorescence recovery was indeed operative depending on the tumor-related angiogenic receptors (αvβ3 integrin and neuropilin-1) in vitro as well as in vivo. Compared to an ‘always fluorescent’ iRGD control probe without quencher conjugation, the dye/quencher-conjugated activatable monolithic peptide probe visualized tumor regions more precisely with lower background noise after intravenous injection, owing to the multifunctional responses specific to tumor microenvironment. All these results, along with minimal in vitro and in vivo toxicity profiles, suggest potential of the iRGD-based activatable monolithic peptide probe as a promising imaging agent for precise tumor diagnosis.

Original languageEnglish
Pages (from-to)177-184
Number of pages8
JournalJournal of Controlled Release
Volume237
DOIs
Publication statusPublished - 2016 Sep 10
Externally publishedYes

Fingerprint

Fluorescence
Neuropilin-1
Neoplasms
Peptides
Integrins
Disulfides
Coloring Agents
Cyclic Peptides
Tumor Microenvironment
N-end cysteine peptide tumor-homing peptide
Fluorescent Dyes
Amides
Intravenous Injections
Cell Communication
Noise
In Vitro Techniques

Keywords

  • Activatable probe
  • Internalizing RGD (iRGD)
  • Peptide monolith
  • Tumor imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Activatable iRGD-based peptide monolith : Targeting, internalization, and fluorescence activation for precise tumor imaging. / Cho, Hong Jun; Lee, Sung Jin; Park, Sung Jun; Paik, Chang H.; Lee, Sang Myung; Kim, Sehoon; Lee, Yoon Sik.

In: Journal of Controlled Release, Vol. 237, 10.09.2016, p. 177-184.

Research output: Contribution to journalArticle

Cho, Hong Jun ; Lee, Sung Jin ; Park, Sung Jun ; Paik, Chang H. ; Lee, Sang Myung ; Kim, Sehoon ; Lee, Yoon Sik. / Activatable iRGD-based peptide monolith : Targeting, internalization, and fluorescence activation for precise tumor imaging. In: Journal of Controlled Release. 2016 ; Vol. 237. pp. 177-184.
@article{3b43e8b8febd489fb420c9d40762617d,
title = "Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging",
abstract = "A disulfide-bridged cyclic RGD peptide, named iRGD (internalizing RGD, c(CRGDK/RGPD/EC)), is known to facilitate tumor targeting as well as tissue penetration. After the RGD motif-induced targeting on αv integrins expressed near tumor tissue, iRGD encounters proteolytic cleavage to expose the CendR motif that promotes penetration into cancer cells via the interaction with neuropilin-1. Based on these proteolytic cleavage and internalization mechanism, we designed an iRGD-based monolithic imaging probe that integrates multiple functions (cancer-specific targeting, internalization and fluorescence activation) within a small peptide framework. To provide the capability of activatable fluorescence signaling, we conjugated a fluorescent dye to the N-terminal of iRGD, which was linked to the internalizing sequence (CendR motif), and a quencher to the opposite C-terminal. It turned out that fluorescence activation of the dye/quencher-conjugated monolithic peptide probe requires dual (reductive and proteolytic) cleavages on both disulfide and amide bond of iRGD peptide. Furthermore, the cleavage of the iRGD peptide leading to fluorescence recovery was indeed operative depending on the tumor-related angiogenic receptors (αvβ3 integrin and neuropilin-1) in vitro as well as in vivo. Compared to an ‘always fluorescent’ iRGD control probe without quencher conjugation, the dye/quencher-conjugated activatable monolithic peptide probe visualized tumor regions more precisely with lower background noise after intravenous injection, owing to the multifunctional responses specific to tumor microenvironment. All these results, along with minimal in vitro and in vivo toxicity profiles, suggest potential of the iRGD-based activatable monolithic peptide probe as a promising imaging agent for precise tumor diagnosis.",
keywords = "Activatable probe, Internalizing RGD (iRGD), Peptide monolith, Tumor imaging",
author = "Cho, {Hong Jun} and Lee, {Sung Jin} and Park, {Sung Jun} and Paik, {Chang H.} and Lee, {Sang Myung} and Sehoon Kim and Lee, {Yoon Sik}",
year = "2016",
month = "9",
day = "10",
doi = "10.1016/j.jconrel.2016.06.032",
language = "English",
volume = "237",
pages = "177--184",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Activatable iRGD-based peptide monolith

T2 - Targeting, internalization, and fluorescence activation for precise tumor imaging

AU - Cho, Hong Jun

AU - Lee, Sung Jin

AU - Park, Sung Jun

AU - Paik, Chang H.

AU - Lee, Sang Myung

AU - Kim, Sehoon

AU - Lee, Yoon Sik

PY - 2016/9/10

Y1 - 2016/9/10

N2 - A disulfide-bridged cyclic RGD peptide, named iRGD (internalizing RGD, c(CRGDK/RGPD/EC)), is known to facilitate tumor targeting as well as tissue penetration. After the RGD motif-induced targeting on αv integrins expressed near tumor tissue, iRGD encounters proteolytic cleavage to expose the CendR motif that promotes penetration into cancer cells via the interaction with neuropilin-1. Based on these proteolytic cleavage and internalization mechanism, we designed an iRGD-based monolithic imaging probe that integrates multiple functions (cancer-specific targeting, internalization and fluorescence activation) within a small peptide framework. To provide the capability of activatable fluorescence signaling, we conjugated a fluorescent dye to the N-terminal of iRGD, which was linked to the internalizing sequence (CendR motif), and a quencher to the opposite C-terminal. It turned out that fluorescence activation of the dye/quencher-conjugated monolithic peptide probe requires dual (reductive and proteolytic) cleavages on both disulfide and amide bond of iRGD peptide. Furthermore, the cleavage of the iRGD peptide leading to fluorescence recovery was indeed operative depending on the tumor-related angiogenic receptors (αvβ3 integrin and neuropilin-1) in vitro as well as in vivo. Compared to an ‘always fluorescent’ iRGD control probe without quencher conjugation, the dye/quencher-conjugated activatable monolithic peptide probe visualized tumor regions more precisely with lower background noise after intravenous injection, owing to the multifunctional responses specific to tumor microenvironment. All these results, along with minimal in vitro and in vivo toxicity profiles, suggest potential of the iRGD-based activatable monolithic peptide probe as a promising imaging agent for precise tumor diagnosis.

AB - A disulfide-bridged cyclic RGD peptide, named iRGD (internalizing RGD, c(CRGDK/RGPD/EC)), is known to facilitate tumor targeting as well as tissue penetration. After the RGD motif-induced targeting on αv integrins expressed near tumor tissue, iRGD encounters proteolytic cleavage to expose the CendR motif that promotes penetration into cancer cells via the interaction with neuropilin-1. Based on these proteolytic cleavage and internalization mechanism, we designed an iRGD-based monolithic imaging probe that integrates multiple functions (cancer-specific targeting, internalization and fluorescence activation) within a small peptide framework. To provide the capability of activatable fluorescence signaling, we conjugated a fluorescent dye to the N-terminal of iRGD, which was linked to the internalizing sequence (CendR motif), and a quencher to the opposite C-terminal. It turned out that fluorescence activation of the dye/quencher-conjugated monolithic peptide probe requires dual (reductive and proteolytic) cleavages on both disulfide and amide bond of iRGD peptide. Furthermore, the cleavage of the iRGD peptide leading to fluorescence recovery was indeed operative depending on the tumor-related angiogenic receptors (αvβ3 integrin and neuropilin-1) in vitro as well as in vivo. Compared to an ‘always fluorescent’ iRGD control probe without quencher conjugation, the dye/quencher-conjugated activatable monolithic peptide probe visualized tumor regions more precisely with lower background noise after intravenous injection, owing to the multifunctional responses specific to tumor microenvironment. All these results, along with minimal in vitro and in vivo toxicity profiles, suggest potential of the iRGD-based activatable monolithic peptide probe as a promising imaging agent for precise tumor diagnosis.

KW - Activatable probe

KW - Internalizing RGD (iRGD)

KW - Peptide monolith

KW - Tumor imaging

UR - http://www.scopus.com/inward/record.url?scp=84978388546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978388546&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2016.06.032

DO - 10.1016/j.jconrel.2016.06.032

M3 - Article

C2 - 27349354

AN - SCOPUS:84978388546

VL - 237

SP - 177

EP - 184

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -